US Biopharma IPOs: Market's Rally Passes Them By
This article was originally published in Start Up
| Table |
|---|
Advertisement
Topics
- Industries
- BioPharmaceutical
- Subjects
- Business Strategies
- Leadership
Related Companies
Related Deals
- Endocyte nets $80.9mm through its IPO
- Pacira Pharmaceuticals nets $39.1mm through its IPO
- Pain-focused AcelRx goes public, netting $37.7mm
- Otsuka nets Yen198.6bn via its IPO on the Tokyo Stock Exchange
- Talecris brings in $550mm through its IPO
- Aveo Pharmaceuticals closes IPO and nets $83.4mm
- Schering-Plough gets Aveo's AV299 for cancer; ends deal
- IPO raises $67mm for Anacor
- Trius nets $45.6mm via IPO
- Supernus nets $48.8mm in initial public offering
- Clarus Therapeutics files for its IPO; withdrawn
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC092081
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
SC092081
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.